{"id":754883,"date":"2023-05-04T09:28:09","date_gmt":"2023-05-04T13:28:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/"},"modified":"2023-05-04T09:28:09","modified_gmt":"2023-05-04T13:28:09","slug":"lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/","title":{"rendered":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023<\/b><\/p>\n<p>CARLSBAD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=53392436&amp;newsitemid=20230504005102&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=ed1d968781e5fcb23c7b8dd73313d7ea\">Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2023 financial and operating results and to provide a business update.<\/p>\n<p>\nInterested parties may access the conference call on May 11<sup>th<\/sup>, 2023, by dialing (800) 715-9871 from the U.S. and Canada and should request the \u201cLineage Cell Therapeutics Call\u201d. A live webcast of the conference call will be available online in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.lineagecell.com%2Fevents-and-presentations%2Fupcoming-events&amp;esheet=53392436&amp;newsitemid=20230504005102&amp;lan=en-US&amp;anchor=Investors&amp;index=2&amp;md5=ea0e0e5c9724b494d85e98e5963ba595\">Investors<\/a> section of Lineage\u2019s website. A replay of the webcast will be available on Lineage\u2019s website for 30 days and a telephone replay will be available through May 18, 2023, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 8339383.<\/p>\n<p><b>About Lineage Cell Therapeutics, Inc.<br \/>\n<br \/><\/b>Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage\u2019s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage\u2019s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (\u201coff-the-shelf\u201d) product candidates: (i) OpRegen<sup>\u00ae<\/sup>, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.lineagecell.com%2Fnews-releases%2Fnews-release-details%2Flineage-establishes-exclusive-worldwide-collaboration-genentech&amp;esheet=53392436&amp;newsitemid=20230504005102&amp;lan=en-US&amp;anchor=developed&amp;index=3&amp;md5=31af8d4036addb22b3be6b3740cb773d\">developed<\/a> under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage\u2019s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com&amp;esheet=53392436&amp;newsitemid=20230504005102&amp;lan=en-US&amp;anchor=www.lineagecell.com&amp;index=4&amp;md5=d8d0d68a1d624ed18dd1a26a5aed0b28\">www.lineagecell.com<\/a> or follow the company on Twitter <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FLineageCell&amp;esheet=53392436&amp;newsitemid=20230504005102&amp;lan=en-US&amp;anchor=%40LineageCell&amp;index=5&amp;md5=d47d97a3c4acca8cb3721f5509d5b8c3\">@LineageCell<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230504005102\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230504005102\/en\/<\/a><\/span><\/p>\n<p><b>Lineage Cell Therapeutics, Inc. IR<br \/>\n<\/b><br \/>Ioana C. Hone<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:ir@lineagecell.com\">ir@lineagecell.com<\/a>)<br \/>\n<br \/>(442) 287-8963<\/p>\n<p><b>LifeSci Advisors<br \/>\n<\/b><br \/>Daniel Ferry<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:daniel@lifesciadvisors.com\">daniel@lifesciadvisors.com<\/a>)<br \/>\n<br \/>(617) 430-7576<\/p>\n<p><b>Russo Partners \u2013 Media Relations<br \/>\n<\/b><br \/>Nic Johnson or David Schull<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:Nic.johnson@russopartnersllc.com\">Nic.johnson@russopartnersllc.com<\/a>)<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:David.schull@russopartnersllc.com\">David.schull@russopartnersllc.com<\/a>)<br \/>\n<br \/>(212) 845-4242<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biometrics Health Genetics Stem Cells Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230504005102\/en\/1765407\/3\/LINEAGE_2023_RGB_JPG_1740x360.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on May 11th, 2023, by dialing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754883","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on May 11th, 2023, by dialing &hellip; Continue reading &quot;Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T13:28:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023\",\"datePublished\":\"2023-05-04T13:28:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/\"},\"wordCount\":528,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/\",\"name\":\"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-04T13:28:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk","og_description":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on May 11th, 2023, by dialing &hellip; Continue reading \"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T13:28:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023","datePublished":"2023-05-04T13:28:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/"},"wordCount":528,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/","name":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-04T13:28:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005102r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2023-financial-results-and-provide-business-update-on-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754883"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}